This year was a very challenging year for all of us. All the more we would like to thank you for your loyalty and for believing in us.

After the tremendous success of the FOCAL2019 in Miami, the annual conference on the Frontiers in Oncologic Prostate Care and Ablative Local Therapy FOCAL2020 took place virtually where a lot of participants from the world over attended this cutting-edge meeting despite Covid-19 restrictions.

mpMRI has dramatically changed how urologists diagnose and monitor prostate cancer, as it not only allows lesions to be targeted in biopsies but also helps in deciding which patients to biopsy.

Promising preliminary results from HIVEC-HR randomized trial with 24 months of median follow-up, presented by a group of urologists from the Hospital Universitario 12 de Octubre, Madrid, peaked great interest at AUA 2020, because of the growing need to find a valid alternative to BCG for patients with non-muscle invasive bladder cancer (NMIBC).

A group of urologists from Weill Cornell Medicine, New York, NY and Urological Research Network, Miami, FL has presented an interesting pilot study of the feasibility and reproducibility of performing MR/US cryoablation using the MR/US fusion from the Artemis® platform in a step-by-step video at AUA University podcast online.

The great editorial by Dr. Paul Cathcart, a UK expert of salvage robotic radical prostatectomy, has been recently published in the British Journal of Urology International.

We are delighted to announce the WiScope® single-use digital flexible cystoscope, which recently received EU approval and is based on the same imaging platform as a WiScope® single-use flexible digital ureteroscope.

As the global infection rates of COVID-19 continue to rise, investigators in Italy, led by Erika Poggiali, M.D., from Ospedale Guglielmo da Saliceto, evaluated whether lung ultrasound could be an effective tool in also identifying patients who have pneumonia specifically associated with the virus. They published their results in a Letter to the Editor recently in Radiology.

We continue to monitor the COVID-19 outbreak and are adjusting our business practice in line with directives from the BAG and WHO. It is our goal to give ongoing support to our customers while at the same time ensuring the safety and health of our team members.

At the ASCO Genitourinary Cancers Symposium 2020 in San Francisco, Prof. Thomas-Alexander Vögeli from the University Hospital RWTH Aachen, Germany presented very promising results of first two year follow up after the Hyperthermic Intra-VEsical Chemotherapy (HIVEC) with heated mitomycin in a cohort of patients with high risk superficial bladder cancer (TCC).

Impressive results of the COMPARE study have recently been published in The Journal of Urology. Prostate cancer patients of all risk groups were willing to trade-off cancer-specific survival for improved quality of life.

As 2019 comes to an end, this is our time to say thank you.